Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is expected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Beam Therapeutics to post earnings of ($1.15) per share and revenue of $8.75 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million for the quarter, compared to the consensus estimate of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. Beam Therapeutics’s quarterly revenue was down 94.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.00) earnings per share. On average, analysts expect Beam Therapeutics to post ($4.49) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Beam Therapeutics Stock Down 1.1%

BEAM stock opened at $23.79 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. Beam Therapeutics has a 1 year low of $20.23 and a 1 year high of $38.26. The stock’s fifty day moving average price is $25.96 and its 200-day moving average price is $28.23.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BEAM. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Beam Therapeutics in a research note on Thursday, October 15th. William Blair raised shares of Beam Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Wedbush reiterated an “outperform” rating and issued a $65.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, October 14th. Finally, Wall Street Zen upgraded shares of Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.10.

Insider Activity

In other news, CEO John Evans sold 25,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total value of $589,250.00. Following the completion of the sale, the chief executive officer directly owned 1,047,205 shares in the company, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.80% of the stock is currently owned by insiders.

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.